Efficacy of Vitamin K as a supplement in Osteoporosis
|
|
- Merry May
- 6 years ago
- Views:
Transcription
1 2014; 2 (6): ISSN: EJBB 2014; 2 (6): Received: Accepted: Fazeel ZA Senior Resident, Dept. of Pharmacology, Gandhi Medical College, Secunderabad, India. Ghina Fazeelath Post Graduate, Dept. of Biochemistry, Deccan College of Medical Sciences, Hyderabad, India Efficacy of Vitamin K as a supplement in Osteoporosis Fazeel ZA, Ghina Fazeelath Abstract Osteoporosis is characterized by decreased bone strength, weak skeletal microarchitecture and low BMD. It manifests as pain in weight bearing bones with increased incidence of fractures. Measurement of BMD and serum osteocalcin are 2 of the various methods to diagnose osteoporosis. Various treatment options for osteoporosis have their own side effect profile or failure rate. Certain studies have demonstrated supplementation of vitamin K to enhance effect of anti-osteoporotic treatment. Vitamin K is a fat soluble vitamin involved in Blood coagulation. Blood coagulation is carried out by gamma carboxylation of factors II, VII, IX and X. in the similar manner vitamin K causes Gamma carboxylation of osteocalcin. Osteocalcin is a protein which binds to hydroxyapatite in bone matrix and promotes bone formation. Various studies have been compiled in this article that have demonstrated the beneficial effect of vitamin K in various types of osteoporosis post menopausal, disuse induced, drug induced. Keywords: Osteoporosis vitamin K Osteocalcin BMD Post-Menopausal 1. Introduction Osteoporosis is a condition where bone strength is decreased. It is seen in both men and women having conditions associated with bone demineralization. Osteoporosis is seen in > 10 million population in the USA and close to 25 million in India. Histologically osteoporosis manifests as defective bone mineralization leading to weak skeletal microarchitecture. Clinically, osteoporosis manifests as pain in weight bearing bones with increased incidence of fractures. Measurement of Bone Mineral Density (BMD) is a crucial investigation for diagnosis of osteoporosis. Several biochemical markers related to bone formation or bone resorption provide an index to overall rate of bone remodeling. These markers are usually used to assess treatment response. For example, serum osteocalcin is one of the markers for bone formation [1]. Treatment options for osteoporosis include calcium and vitamin D supplementation, estrogen replacement therapy, anabolic steroids, etc [2]. Certain studies have demonstrated supplementation of vitamin K to enhance effect of anti-osteoporotic treatment. 2. Vitamin K Vitamin K is a fat soluble vitamin which comprises of structurally similar fat soluble molecules Phylloquinone (K 1), Menaquinone (K 2) and Menadione (K 3). Phylloquinone (K 1) also called as phytonadione is obtained from plant sources such as green leafy vegetables. Vitamin K 1 content in green leafy vegetables is about ng/g; while that in Cheese and curd is about ng/g [3]. Menaquinone (K 2) is of bacterial origin [4]. Menadione (K 3) is a synthetic molecule [5] recommended daily allowance of vitamin K is mcg/day [6]. Correspondence: Fazeel ZA Senior Resident, Dept. of Pharmacology, Gandhi Medical College, Secunderabad, India. fazeel_zubair@yahoo.com 2.1 Functions of Vitamin K Blood coagulation is the major function of vitamin K. Blood coagulation by vitamin K is carried out by gamma carboxylation of coagulation proteins such as factors II, VII, IX and X. In this reaction, reduced vitamin K acts via gamma glutamyl carboxylase enzyme to deprotonate glutamate residue of target proteins. This deprotonation leads to oxidation of vitamin K (KO) which is recycled to reduced vitamin K (KH) by the enzyme vitamin K epoxide. ~ 25 ~
2 Among all the isoforms of Vitamin K, Menaquinone (K 2) has most potent carboxylation activity [7]. 2.2 Role of Vitamin K in bone formation Some bone forming proteins such as osteocalcin require gamma carboxylation in order to get into their active form. Gamma carboxylation of osteocalcin occurs in the same way as blood clotting factors. Osteocalcin is synthesized by osteoblasts. Its function is to bind to hydroxyapatite in bone matrix in order to promote bone formation [8]. Osteocalcin cannot bind to hydroxyapatite without itself undergoing gamma carboxylation [9]. This fact is supported by the evidence that serum undercarboxylated osteocalcin is raised in vitamin K deficient individuals [10]. However unlike blood clotting factors which require low blood levels of vitamin K, osteocalcin requires higher levels of vitamin K for gamma carboxylation [11]. This fact has been proved by Binkley NC et al., where they studied 219 healthy adult Americans eating daily routine diet. Insufficient vitamin K levels for gamma carboxylation of osteocalcin but sufficient enough to maintain normal prothrombin time were observed in these volunteers [12]. 2.3 Concern about hypercoagulation due to high doses of Vitamin K Asakura et al., administered 15 mg vitamin K 2 three times a day to 29 geriatric patients of osteoporosis for 12 weeks. All hemostatic markers were found to be within normal range after 12 weeks [13]. Ushiroyama et al., studied the effect of combination of vitamin K 2 and vitamin D 3 on BMD in female volunteers of post-menopausal age group. Coagulation factors increased but the effect was counterbalanced by increase in fibrinolysis [14]. Likewise, many such clinical trials have failed to demonstrate hypercoagulability with high dose of vitamin k even up to 40 mg/day [15, 16]. 2.4 Effect of Vitamin K in Osteoporosis Comparison with placebo Orimo et al., recruited 80 osteoporosis patients and grouped them into 2 groups. First group received placebo and second group received vitamin K in dose of 90 mcg/day for 24 weeks. BMD of second metacarpal was recorded before and after treatment. Vitamin K group had shown increase in BMD by 2.20±2.48 % while placebo group had shown decrease in BMD by 7.31±3.65 % [16]. 2.5 Effect of Vitamin K supplementation with calcium Shiraki et al., recruited 241 female osteoporosis patients and grouped them into calcium group and calcium + vitamin K group. Dose of calcium used was 150 mg/day and that of vitamin K was 45 mg/day. Treatment was given for 24 months. After 24 months, calcium + vitamin K group had demonstrated lower fracture incidence of 10% compared calcium group which was 30% [17]. 2.6 Effect of Vitamin K and Vitamin D3 cosupplementation Ushiroyama et al., studied 172 female osteoporosis patients having BMD < 0.98 g/cm 2. These women were assigned randomly to one of the 4 groups Vitamin D 3, Vitamin K 2 Vitamin D 3 + K 2 and Placebo. The above treatments were given for 24 months. Vertebral BMD of these patients were recorded at 6 monthly intervals from start of treatment. It was found that vitamin K group increased BMD from18 th month and this effect was comparable to vitamin D 3 alone. However, the combination group had shown highly significant improvement in BMD when compared to its baseline and with other groups (p<0.001). This statistically significant change was observed from 6 th month itself [18]. ~ 26 ~
3 2.7 Effect of Vitamin K supplementation with Bisphosphonates Iwamoto et al., studied 98 post-menopausal women suffering from osteoporosis. They assigned these patients randomly into 4 groups Calcium, Etidronate, Vitamin K, and combination of Etidronate + Vitamin K. Dose of Calcium used was 150 mg/day for 3 months and that of Vitamin K was 45mg/day for 3 months. Etidronate was given in dose of 200 mg/day for 2 weeks/month for 3 months. It was found that incidence of fracture was significantly less in vitamin K (2 of 23 => 8.70 %) and Etidronate (2 of 25 => 8%) compared to calcium group (6 of 24 => 25 %) while fracture incidence was further decreased in combination group (1 of 26 => 3.85 % ) [19]. 2.9 Role of Vitamin K in Leuprolide induced Osteoporosis Gonadotropin releasing hormone antagonists like leuprolide are commonly used for endometriosis, leiomyoma and prostate cancer. Reduction in BMD is one side effect seen in GnRH antagonist treated patients [22, 23]. Somekawa et al., studied 110 patients receiving Leuprolide. These patients were grouped as Leuprolide only group, Vitamin K group, Vitamin D 3 group, and Vitamin K + Vitamin D group. Leuprolide was not withheld for any of the above group. Dose of vitamin K 2 was 45 mg/day and that of vitamin D was 0.5 mcg/day. These patients were followed for 6 months. Lumbar spine BMD was noted before and after the treatments. It was observed that vitamin K prevented bone loss compared to leuprolide only group. This beneficial effect of vitamin K was enhanced significantly when given in combination with vitamin D [24]. 2.8 Role of Vitamin K in Osteopenia due to immobility Immobility is commonly seen in stroke patients whose BMD is lost significantly on the affected side compared to unaffected side. This bone loss occurs due to immobilization induced hypercalcemia and hypovitaminosis D [20]. Sato studied 108 patients of hemiplegic stroke. 54 patients were administered vitamin K for 12 months and 54 patients served as controls. BMD of second metacarpal on hemiplegic side increased by 4.3% in vitamin K treated patients whereas BMD decreased by 4.7% in controls [21] Role of Vitamin K in Osteoporosis associated with Anorexia Anorexia is an eating disorder in which the individual restricts food intake to a large extent in order to lose weight. This leads to malnutrition. Malnutrition further leads to different sets of health problems. 1% of anorexic females suffer from osteoporosis [25]. Iketani et al., studied 21 patients diagnosed with anorexia for 11 months, during which 10 patients were prescribed vitamin K in dose of 45mg/day 11 patients did not consent for vitamin ~ 27 ~
4 K so they were recruited as controls. It was observed that loss of BMD was less in vitamin K treated group (-2.8%) compared to control group (-6.9%) Biochemical marker for activity of Vitamin K in Osteoporosis It would be desirable to have a serum marker for vitamin K in order to check for requirement, activity, and side effects of vitamin K. Serum Osteocalcin serves as a sensitive indicator for vitamin K activity [26]. Osteocalcin is naturally secreted by osteoblasts. It is involved in mineralization and calcium homeostasis. Osteocalcin is a vitamin K dependent calcium binding protein. Certain molecules like 1,25-dihydroxyvitamin D, estrogen, glucocorticoids, etc. regulate transcription of osteocalcin gene. Post translational modification of osteocalcin occurs through vitamin K just like that of blood clotting factors II, VII, IX and X. vitamin K causes gamma carboxylation of glutamate molecules of osteocalcin. This gamma carboxylation is essential for binding of osteocalcin to calcium and thus mediating binding of osteocalcin to hydroxyapatite [27]. In vitamin K deficiency, osteocalcin does not get carboxylated hence termed as Undercarboxylated Osteocalcin (ucoc). This ucoc has decreased affinity for binding to bone and more of it could be detected in blood and urine. Hence high serum levels of ucoc indicates low vitamin K and vice versa. High levels of ucoc have been observed in elderly women [28, 29]. 3. Conclusion Vitamin K plays an important role in bone formation apart from its role in blood coagulation. Vitamin K causes Gamma carboxylation of osteocalcin a bone forming protein, in the same way as that of blood clotting factors. Role of vitamin K in osteoporosis is supported by the fact that undercarboxylated osteocalcin is elevated in osteoporosis patients having physiological or subphysiological vitamin K levels. Supraphysiological doses are required for carboxylation of osteocalcin in osteoporosis. High doses of vitamin K are safe and do not effect prothrombin time. Various studies have proved effectiveness of vitamin K in osteoporosis as a supplement with calcium, vitamin D and bisphosphonates. Effectiveness of vitamin K has been proved in different types of osteoporosis post menopausal, GnRH antagonists induced, anorexia associated, immobility associated, etc. Serum undercarboxylated osteocalcin can be utilized as a serum marker for activity of vitamin K. In present scenario, if vitamin K supplementation cannot be considered due to some reason, consuming vitamin K enriched foods Green vegetables, cheese, curd, fish, meat; could also be beneficial for osteoporosis patients. 4. References 1. Lindsay R, Cosman F. Osteoporosis. In: Longo, Fauci, Kasper, Hauser, Jameson, Loscalzo, editors. Harrison s principles of internal medicine. Edn 18, USA, McGraw Hill, 2012, Friedman PA. Agents Affecting Mineral Ion Homeostasis and Bone Turnover. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman s The pharmacological basis of therapeutics. Edn 12, New York, McGraw-Hill, 2011, Thomson RH. Naturally Occurring Quinones. New York, Academic Press, Thijssen HH, Drittij-Reijnders MJ. Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. Br J Nutr 1996; 75: Budavari S. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. Rahway, NJ, Merck, Bender DA. Micronutrients: Vitamins & Minerals. In: Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA, editors. Harper s illustrated biochemisty. Edn 29, New York, McGraw-Hill, Plaza SM, Lamson DW. Vitamin K2 in Bone Metabolism and Osteoporosis. Alternative Medicine Review 2005; 10(1): Inoue T, Sugiyama T, Matsubara T, Kawai S, Furukawa S. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. Endocr J 2001; 48: Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980; 66: Sokoll LJ, Booth SL, O Brien ME, Davidson KW, Tsaioun KI, Sadowski JA. Changes in serum osteocalcin, plasma phylloquinone, and urinary gammacarboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr 1997; 65(3): Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr 1998; 128: Binkley NC, Krueger D, Engelke JA, Foley AL, and Suttie J W. Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr. 2000; 72: Asakura H, Myou S, Ontachi Y, Mizutani T, Kato M, Saito M et al. Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. Osteoporos Int 2001; 12: ~ 28 ~
5 14. Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 2002; 41: Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15: Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebocontrolled study. J Bone Miner Metab. 1998; 16: Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15: Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 2002; 41: Iwamoto J, Takeda T, Ichimura S. Combined treatment with vitamin K2 and bisphosphonate in postmenopausal women with osteoporosis. Yonsei Med J 2003; 44: Sato Y, Kuno H, Kaji M, Ohshima Y, Asoh T, Oizumi K. Increased bone resorption during the first year after stroke. Stroke 1998; 29: Sato Y, Honda Y, Kuno H, Oizumi K. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998; 23: Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345: Dawson-Hughes B. Bone loss accompanying medical therapies. N Engl J Med. 2001; 345: Somekawa Y, Chigughi M, Harada M, Ishibashi T. Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. J Clin Endocrinol Metab 1999; 84: Schneider M, Fisher M, Weinerman S, Lesser M. Correlates of low bone density in females with anorexia nervosa. Int J Adolesc Med Health. 2002; 14: Sokoll LJ, Booth SL, O Brien ME, Davidson KW, Tsaioun KI, Sadowski JA. Changes in serum osteocalcin, plasma phylloquinone, and urinary gammacarboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr. March 1997; 65(3): Vermeer C, Jie KS, Knapen MH. Role of vitamin K in bone metabolism. Annu Rev Nutr. 1995; 15: Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. Apr 1993; 91(4): ~ 29 ~
A high phylloquinone intake is required to achieve maximal osteocalcin -carboxylation 1 3
A high phylloquinone intake is required to achieve maximal osteocalcin -carboxylation 1 3 Neil C Binkley, Diane C Krueger, Tisha N Kawahara, Jean A Engelke, Richard J Chappell, and John W Suttie ABSTRACT
More informationREVIEW ARTICLE. Vitamin K and the Prevention of Fractures. Systematic Review and Meta-analysis of Randomized Controlled Trials
REVIEW ARTICLE Vitamin K and the Prevention of Fractures Systematic Review and Meta-analysis of Randomized Controlled Trials Sarah Cockayne, MSc; Joy Adamson, PhD; Susan Lanham-New, PhD; Martin J. Shearer,
More informationBiochemistry of Vitamin K
Lecture 4 Biochemistry of Vitamin K The Objectives Types and chemistry of vitamin K Sources and daily requirements Functions Synthesis of γ-carboxyglutamate in: Prothrombin and blood clotting factors Osteocalcin
More informationNEW MK-7 SELECT INTRODUCTION
NEW MK-7 SELECT INTRODUCTION As we have all known for several years now, the presence of optimal amounts of vitamin D is essential for maintaining optimal bone health and bone calcification, as noted by
More informationVitamin K status of healthy Japanese women: age-related vitamin K requirement for -carboxylation of osteocalcin 1 3
Vitamin K status of healthy Japanese women: age-related vitamin K requirement for -carboxylation of osteocalcin 1 3 Naoko Tsugawa, Masataka Shiraki, Yoshitomo Suhara, Maya Kamao, Kiyoshi Tanaka, and Toshio
More informationEfficacy of Vitamin K2 for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases
ORIGINAL ARTICLE Efficacy of Vitamin K2 for Glucocorticoid-induced Osteoporosis in Patients with Systemic Autoimmune Diseases Kotaro Shikano 1, Kaichi Kaneko 1, Mai Kawazoe 1, Makoto Kaburaki 1, Tomoko
More informationK K MK-4 MK-4 1,25-D3
22 5 13 D 25-Hydroxyvitamin D Gla K K D K D K K K -4MK-4 MK-4 MK-4 steriod and xenobiotic receptorsxr MK-4 SXR MK-4 K MK-4 D 1,25-D3 D 1 CYP27B1CYP27B1-KO D CYP27B1-KO D D CYP27B1-KO Ca 1,25-D3 D Vitamin
More informationVitamin K Snapshot Monograph
vitamins minerals nutrients Vitamin K Snapshot Monograph Vitamin K1 and Vitamin K2 Most Frequent Reported Uses: Blood clotting Anticoagulant reversal; bleeding disorders Osteoporosis prevention Arthritis,
More informationVitamin K intake and bone mineral density in women and men 1 4
Vitamin K intake and bone mineral density in women and men 1 4 Sarah L Booth, Kerry E Broe, David R Gagnon, Katherine L Tucker, Marian T Hannan, Robert R McLean, Bess Dawson-Hughes, Peter WF Wilson, L
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationEpidemiological evidence has shown associations between. Effect of Vitamin K Supplementation on Bone Loss in Elderly Men and Women
ORIGINAL ARTICLE Endocrine Care Effect of Vitamin K Supplementation on Bone Loss in Elderly Men and Women Sarah L. Booth, Gerard Dallal, M. Kyla Shea, Caren Gundberg, James W. Peterson, and Bess Dawson-Hughes
More informationINTERNATIONAL JOURNAL OF PHARMACOLOGY AND THERAPEUTICS ISSN Original Article
Original Article THE STUDY OF RELATIONSHIP BETWEEN UNDERCARBOXILATED OSTEOCALCIN AND ADMINISTRATION OF VITAMIN K 2, VITAMIN D 3 AND CALCIUM IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL OSTEOPENIC WOMEN
More informationVitamin K. Amina Ziyad Elaf Sohaib
Vitamin K Amina Ziyad Elaf Sohaib What is Vitamin K? Fat soluble compound Necessary for the synthesis of several proteins required for blood clotting 1) Vit K 1 (Phylloquinone) - natural form - found in
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationDoes vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials
DOI 10.1007/s00198-014-2989-6 ORIGINAL ARTICLE Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials Z.-B.
More informationLow serum and bone vitamin K status in patients with longstanding Crohn s disease: another pathogenetic factor of osteoporosis in Crohn s disease?
Gut 2001;48:473 477 473 Department of Gastroenterology and Hepatology, University Hospital Maastricht, Maastricht, the Netherlands E J Schoon M C A Müller R-J M Brummer R W Stockbrügger Department of Biochemistry,
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationVitamin K intake and hip fractures in women: a prospective study 1 3
Vitamin K intake and hip fractures in women: a prospective study 1 3 Diane Feskanich, Peter Weber, Walter C Willett, Helaine Rockett, Sarah L Booth, and Graham A Colditz ABSTRACT Background: Vitamin K
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationIs warfarin usage a risk factor for osteoporotic fractures? A cohort study in the emergency department
Is warfarin usage a risk factor for osteoporotic fractures? A cohort study in the emergency department Genady Drozdinsky 1, Jonah B. Cohen 2, Zipora Shohat 3,4, Shachaf Shiber-Ofer 3,5, Alon Grossman 3,6
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationBONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis
BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationProtecting Bone and Arterial Health with Vitamin k2
http://www.lef.org/ LE Magazine March 2008 Protecting Bone and Arterial Health with Vitamin k2 By William Davis, MD Millions of people take calcium supplements to maintain healthy bone. Yet few patients
More informationThe most important human clinical trials on Vitamin K2
References update The most important human clinical trials on Vitamin K2 REFERENCES UPDATE Cardiovascular Health Bone Health Kidney Health Other (Efficacy, Dose Finding, Absorption, etc.) Beneficial Effects
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationBRITISH BIOMEDICAL BULLETIN
Journal Home Page www.bbbulletin.org BRITISH BIOMEDICAL BULLETIN Original Cost Analysis of Z-Drugs in Indian Market: A Pharmacoeconomic Study Fazeel ZA* Post Graduate, Department of Pharmacology, Kamineni
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationChanges in Skeletal Systems over the Lifespan. Connie M. Weaver, Ph.D. Purdue University
Changes in Skeletal Systems over the Lifespan Connie M. Weaver, Ph.D. Purdue University Disclosures Boards/Scientific Advisory Committees ILSI Showalter Pharmavite Grants NIH Dairy Research Institute Nestle
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationWho should receive calcium and vitamin D supplementation?
Age and Ageing Advance Access published August 8, 2012 Age and Ageing 2012; 0: 1 5 The Author 2012. Published by Oxford University Press on behalf of the British Geriatrics Society. doi: 10.1093/ageing/afs094
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationHelpful information about bone health & osteoporosis Patient Resource
Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half
More informationVitamin K in Cystic Fibrosis
Vitamin K in Cystic Fibrosis Martin J. Shearer PhD, MRCPath Consultant Clinical Scientist Honorary Senior Lecturer Centre for Haemostasis and Thrombosis, Guy s and St. Thomas Foundation Trust London, UK
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationComparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis
Yonsei Medical Journal Vol. 46, No. 6, pp. 750-758, 2005 Original Article Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis
More informationThe number of disabled elderly stroke survivors has
Vitamin D Deficiency and Risk of Hip Fractures Among Disabled Elderly Stroke Patients Yoshihiro Sato, MD; Takeshi Asoh, MD; Izumi Kondo, MD; Kei Satoh, MD Background and Purpose Risk of hip fracture after
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationLearning Objectives. ! Students will become familiar with the 3 treatment solutions for osteoporosis. ! Students should be able to define osteoporosis
Learning Objectives! Students should be able to define osteoporosis! Students should be able to identify some risk factors of osteoporosis! Students should be able to identify some of the people in the
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationBone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017
Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests
More informationCalcium and vitamin D nutrition and bone disease of the elderly
Public Health Nutrition: 4(2B), 547±559 DOI: 10.1079/PHN2001140 Calcium and vitamin D nutrition and bone disease of the elderly C Gennari* Institute of Internal Medicine, University of Siena, Italy Abstract
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationThe relationship between daily calcium intake and bone mineral density in men with prostate cancer
Original Article DAILY CALCIUM INTAKE AND BONE MINERAL DENSITY IN PROSTATE CANCER PLANAS ET AL. The relationship between daily calcium intake and bone mineral density in men with prostate cancer Jacques
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationSultan Qaboos University. College of Agricultural & Marine Sciences. Vitamin K. Lecture Summary
Sultan Qaboos University College of Agricultural & Marine Sciences Vitamin K Lecture Summary Name: Mohsin Mohammed Taqi Mohsin Al-Saleh ID #: M020944-99 0 Introduction: Vitamin K is a group of structurally
More informationEfficacy of Oral Etidronate for Skeletal Diseases in Japan
Yoei Medical Journal Vol. 46, No. 3, pp. 313-320, 2005 Review Article Efficacy of Oral Etidronate for Skeletal Diseases in Japan Jun Iwamoto 1, Tsuyoshi Takeda 1, and Yoshihiro Sato 2 1 Department of Sports
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationHypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement. Hypothalamic amenorrhea NASPAG ACRM 2015
Hypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement Meredith Loveless, MD Gina Sucato, MD MPH NASPAG ACRM 2015 Hypothalamic amenorrhea Functional hypothalamic amenorrhea Absence
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationEFFECT OF INTRAVENOUS ZOLENDRONIC ACID ON BONE MINERAL DENSITY IN POST MENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY OF NORTH WEST PART OF RAJASTHAN
International Journal of Advanced Research and Review www.ijarr.in EFFECT OF INTRAVENOUS ZOLENDRONIC ACID ON BONE MINERAL DENSITY IN POST MENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY OF NORTH WEST PART
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationCOURSE OUTLINE - Module I
Module II MEDICAL DISCLAIMER The information in this program is for educational purposes only. It is meant to as a guide towards health and does not replace the evaluation by and advice of a qualified
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationThe Better Health News2
October, 2016 Volume11, Issue 10 The Better Health News2 Special Interest Articles: Menopause and Bioflavonoids Osteoporosis and Exercise Bone Health: More than Calcium & Vitamin D Flax Seeds and Menopause
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationBenefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones
Benefits of Calcium and Vitamin D: Building and Maintaining Healthy Bones Prepared by Annette Dickinson, Ph.D. Council for Responsible Nutrition June 2002 There is no question that a generous intake of
More information